Tamara D.
- Country
- Spain
- Department
- Medical oncology
Research Overview
- Phase III Randomized Controlled Trial of Abemaciclib Plus Endocrine Therapy Versus Endocrine Therapy in HR+/HER2- Early Breast Cancer with Intermediate to High Risk
- Phase 3 Randomized Study of Pembrolizumab and Lenvatinib Versus Chemotherapy in Advanced or Recurrent Endometrial Carcinoma
- Phase III Randomized Double-Blind Study of Alpelisib and Fulvestrant in HR-Positive, HER2-Negative Advanced Breast Cancer with PIK3CA Mutation
Data & Insights
Has run more than one trial at 11 of 185 partner sites.
Specializations
Breast Cancer Research
The investigator specializes in treating hormone receptor-positive (HR+) and HER2-negative breast cancer, with particular emphasis on early-stage disease management.
- Early-stage breast cancer interventions
- Hormone receptor-positive disease treatment
- Endocrine therapy optimization
The research focus includes developing personalized therapeutic approaches for patients with intermediate to high-risk breast cancer profiles.
Personalized Medicine
This investigator advances dynamic marker-adjusted personalized therapy approaches in oncology, integrating clinical and genomic risk assessments to guide treatment decisions.
- Biomarker-driven treatment selection
- Risk-adapted therapy strategies
- Personalized treatment optimization
The work emphasizes tailoring treatments based on individual patient characteristics and disease markers.
Therapeutic Innovation
The investigator explores novel therapeutic combinations in breast cancer treatment, particularly focusing on integrating targeted therapies with standard endocrine treatments.
- Combined therapy approaches
- Treatment efficacy assessment
- Disease-free survival optimization
Research efforts concentrate on enhancing treatment outcomes through innovative therapeutic strategies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.